Gentium Announces Presentation Of Defibrotide Data At The American Society Of Hematology
VILLA GUARDIA, Italy, Nov. 10, 2010 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that three abstracts on Defibrotide will be presented at the 52 nd Annual Meeting and Exposition of the American Society of Hematology to be held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.
Poster session: Clinical Care – Transplantation Regimen Toxicities and Engraftment: Poster II, Hall A3/A4, Monday, December 6, 2010, 6:00 PM - 8:00 PM
"Meta-analysis of Defibrotide (DF) in the treatment of severe hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with comparison to a Historical Control (HC)" (Poster Board III-260). P. Richardson et. al., Dana-Farber Cancer Institute, Boston, MA, USA."Safety of Defibrotide (DF) in Stem Cell Transplant (SCT) patients (Pts)" (Poster Board III-261). S. Corbacioglu et al., University of Regensburg, Regensburg, Germany. Oral session: Clinical Care – Transplantation Regimen Toxicities and Engraftment: Transplant Related Toxicities, Room 110A, Tuesday, December 7, 2010, 8:45 AM "Defibrotide (DF) in the treatment of severe hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): results of a treatment IND expanded access protocol" (Abstract #906), P. Richardson et. al., Dana-Farber Cancer Institute, Boston, MA, USA. For more details on the congress, please visit the official congress web site: http://www.hematology.org/Meetings/Annual-Meeting/ About Gentium Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. FDA and Orphan Medicinal Product Designation by the European Commission both to treat and to prevent VOD and Fast Track Designation by the U.S. FDA to treat VOD.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV